Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHA OTCMKTS:IPHYF NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$1.81$1.67$1.17▼$2.63$170M0.3140,876 shs1,668 shsIPHYFInnate Pharma$1.65$1.68$1.37▼$2.25$138.32M0.27335 shsN/AOCGNOcugen$1.24$1.48$0.90▼$2.73$419.77M2.196.22 million shs26.26 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.69%+4.02%-10.84%+54.70%-4.74%IPHYFInnate Pharma0.00%0.00%-26.67%-23.43%-4.90%OCGNOcugen+0.81%+1.64%-4.62%-39.22%+13.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$1.81$1.67$1.17▼$2.63$170M0.3140,876 shs1,668 shsIPHYFInnate Pharma$1.65$1.68$1.37▼$2.25$138.32M0.27335 shsN/AOCGNOcugen$1.24$1.48$0.90▼$2.73$419.77M2.196.22 million shs26.26 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.69%+4.02%-10.84%+54.70%-4.74%IPHYFInnate Pharma0.00%0.00%-26.67%-23.43%-4.90%OCGNOcugen+0.81%+1.64%-4.62%-39.22%+13.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 2.50Moderate Buy$5.00176.24% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AOCGNOcugen 2.60Moderate Buy$9.50666.13% UpsideCurrent Analyst Ratings BreakdownLatest OCGN, IPHYF, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026IPHAInnate Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/25/2026OCGNOcugen Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/25/2026OCGNOcugen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$10.19M16.68N/AN/A($0.26) per share-6.96IPHYFInnate Pharma$10.19M13.57N/AN/A($0.29) per share-5.69OCGNOcugen$4.41M95.18N/AN/A($0.04) per share-31.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/AIPHYFInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/AOCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)Latest OCGN, IPHYF, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate PharmaN/A1.271.27IPHYFInnate PharmaN/A1.271.27OCGNOcugen4.171.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%IPHYFInnate PharmaN/AOCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%IPHYFInnate Pharma31.89%OCGNOcugen3.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22093.92 million63.97 millionNot OptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableOCGNOcugen80338.52 million325.15 millionOptionableOCGN, IPHYF, and IPHA HeadlinesRecent News About These CompaniesOcugen (NASDAQ:OCGN) CFO Treerita Essali Johnson-Greene Acquires 21,000 SharesJune 18 at 8:44 AM | insidertrades.comHow The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst GuidanceJune 5, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | zacks.comOcugen Consolidates Financial Leadership Under New Accounting OfficerJune 3, 2026 | tipranks.comOcugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareJune 3, 2026 | zacks.comIs OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?June 3, 2026 | zacks.comOCGN's Catalyst Calendar for Trial Data and Filings Through 2028June 3, 2026 | zacks.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | finance.yahoo.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | globenewswire.comOcugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exitMay 26, 2026 | msn.comOcugen Announces Interim Chief Medical Officer Appointment TransitionMay 14, 2026 | tipranks.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | finance.yahoo.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | globenewswire.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | finance.yahoo.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | finance.yahoo.comOcugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 ConferencesMay 13, 2026 | quiverquant.comQOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | markets.businessinsider.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCGN, IPHYF, and IPHA Company DescriptionsInnate Pharma NASDAQ:IPHA$1.82 +0.00 (+0.28%) As of 06/18/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Innate Pharma OTCMKTS:IPHYF$1.65 0.00 (0.00%) As of 06/18/2026Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Ocugen NASDAQ:OCGN$1.24 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.42%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
